Wyeth Remake Analyst Meeting 10-05-06 slides 4-8

1,071 views

Published on

Published in: Business, Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,071
On SlideShare
0
From Embeds
0
Number of Embeds
51
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Wyeth Remake Analyst Meeting 10-05-06 slides 4-8

  1. 1. Remake of October 5, 2006 Wyeth Analyst Meeting slides 4-8 http://phx.corporate-ir.net/phoenix.zhtml?c=78193&p=irol-presentations
  2. 2. Agenda 4 Break New Products U. Wiinberg Enbrel® & Prevnar® E.A. Emini, Ph.D. Prevnar 13 R. Essner Introduction J. Victoria Welcome Tygacil® J.S. Camardo, M.D. Torisel™ Lybrel™ G. Constantine, M.D. Aprela™ / Viviant™ J.S. Camardo, M.D. Methylnaltrexone R.M. Poole, M.D., FACP Bifeprunox J.M. Mahady Pristiq™ B. Poussot Conclusion and Q&A Key Registration Submissions R.R. Ruffolo, Jr., Ph.D. Mid-Pipeline Review
  3. 3. Introduction 5 Robert Essner Chairman and Chief Executive Officer, Wyeth
  4. 4. Wyeth Past Business Performance 7% 3% 9% 10% 8% Revenue Growth (in billions) 6 WHI
  5. 5. Wyeth Past Business Performance 11% 15% 2% 10% 7% EPS* Growth 7 WHI July Guidance * Before Certain Significant items
  6. 6. EPS Continues to Grow in 2006 12% 11% 15% 2% 10% 7% EPS* Growth 8 WHI +** July Guidance * Before Certain Significant items ** When Adjusted for Stock Option Expensing in 2005

×